Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zacks.com users have recently been watching Walgreens (WBA) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Walgreens Boots Alliance, Inc. (WBA) is Attracting Investor Attention: Here is What You Should Know

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens is now offering flu shots for anyone aged 3 years and up at stores nationwide ahead of respiratory illness season. Individuals and families can visit the pharmacy or schedule an appointment through the Walgreens app, by visiting Walgreens.com/ScheduleVaccine or by calling 1-800-WALGREENS. Walgreens trusted pharmacy teams are working to keep communities protected this upcoming respiratory season by helping to ensure everyone has convenient and timely o.

Walgreens Flu Shot Appointments Now Available Nationwide for Everyone Aged 3 and Up

SAN DIEGO, CA / ACCESSWIRE / August 1, 2024 / Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v.

WBA INVESTOR DEADLINE: Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA).

Investors in Walgreens Boots Alliance, Inc. Should Contact The Gross Law Firm Before September 10, 2024 to Discuss Your Rights – WBA

LOS ANGELES, CA / ACCESSWIRE / July 30, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Head The Walgreens Boots Alliance Inc Securities Fraud Lawsuit With The Schall Law Firm

Annaly Capital

Dividend stocks have crushed non-payers in the return column over the last 50 years. Eight of Wall Street's smartest (and richest) money managers sent shares of artificial intelligence (AI) juggernaut Nvidia to the chopping block in the March-ended quarter.

Forget Nvidia: Top-Tier Billionaires Are Selling It and Piling Into 2 Ultra-High-Yield Dividend Stocks Instead

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024, inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v. Walgreens Boots Alliance, Inc., No. 24-cv-05907 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens as well as certain of Walgreens' top executives with violations of the Securities Exchange Act of 1934.

WBA INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Case

LOS ANGELES, CA / ACCESSWIRE / July 29, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Lead The Walgreens Boots Alliance Inc. Securities Fraud Lawsuit With The Schall Law Firm

DexCom

Super Micro Computer

You don't have to wait any longer for a great crash to arrive. Some S&P 500 stocks are already in a world of hurt.

Worried About A Looming 40% Crash? It's Here Already For 12 Stocks

Edwards Lifesciences

Zimmer Biomet Hlds

Finding value in this market is difficult because the S&P 500 has increased over 50% since its bottom in October 2022. Certainly, you won't find it in technology or mega caps, which have soared due to the AI craze.

3 Healthcare Stocks to Buy at a 52-Week Low in July

NEW YORK , July 29, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Walgreens Boots Alliance, Inc. (NASDAQ: WBA). Shareholders who purchased shares of WBA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.

The Gross Law Firm Reminds Walgreens Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 10, 2024 - WBA

LOS ANGELES, CA / ACCESSWIRE / July 26, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Lead Walgreens Boots Alliance Inc Securities Fraud Lawsuit With The Schall Law Firm

Builders FirstSource

EPAM Systems

The extended bull market we are in has not been one where a rising tide lifts all boats. The S&P 500 is up 15% year-to-date and is 52% higher since October 2022 when the latest run-up began.

Should You Buy the 3 Worst S&P 500 Stocks in Q2?

SAN DIEGO, July 26, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all investors who purchased or otherwise acquired Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024. Walgreens is a global company that delivers retail and pharmacy, and healthcare services across the United States, Europe, and Latin America.

Shareholder Rights Law Firm Robbins LLP Reminds Stockholders of the Opportunity to Lead the Walgreens Boots Alliance, Inc. (WBA) Class Action

Medical Properties Trust

Medical Properties Trust's top tenant filed for bankruptcy. Walgreens Boots Alliance faces a highly challenging operating environment.

2 Ultra-High-Yield Dividend Stocks Down More Than 50% Over the Past Year: Are They Dirt-Cheap Buys Now?

NEW ORLEANS, July 24, 2024 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until September 10, 2024 to file lead plaintiff applications in a securities class action lawsuit against Walgreens Boots Alliance, Inc. (NasdaqGS: WBA), if they purchased the Company's securities between October 12, 2023 to June 26, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.

WALGREENS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Walgreens Boots Alliance, Inc. – WBA

LOS ANGELES, CA / ACCESSWIRE / July 24, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Can Lead Walgreens Boots Alliance Inc. Securities Fraud Lawsuit With The Schall Law Firm

Domino's Pizza

Tyson Foods

Everyone's definition of “consumer stocks” is different.  Strictly speaking, I would say that companies operating in the consumer discretionary sector are the best examples of consumer stocks.

Get Your Money Out of These 3 Consumer Stocks by 2025

Walgreens has been cutting costs, but it needs to take more extreme measures given its low margins. From closing stores to scaling back expansion opportunities, there are many levers the company can pull.

5 Things Walgreens Boots Alliance Can Do to Turn Things Around

Coca-Cola

Verizon

Many investors flock to high-yield dividend stocks because they offer a simple premise. You can put your money into a stock and generate high cash flow that gets treated more favorably when it's time to file taxes.

High-Yield Flops: Sell These 3 Stocks Now

NEW YORK, July 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than September 10, 2024.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Walgreens Boots Alliance, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WBA

LOS ANGELES, CA / ACCESSWIRE / July 23, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ: WBA ) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 12, 2023 and June 26, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before September 10, 2024.

WBA Investors Have The Opportunity To Lead Walgreens Boots Alliance Inc. Securities Fraud Lawsuit With The Schall Law Firm

DEERFIELD, Ill.--(BUSINESS WIRE)--Walgreens today announced it received a project award valued up to $25 million through the Rapid Response Partnership Vehicle (RRPV) to conduct a Phase IV observational clinical study focused on assessing Correlates of Protection (CoP), known as responses to a vaccine that predict how well a vaccinated person will be protected from future infections, using COVID-19 vaccine data. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development.

Walgreens Receives BARDA Project NextGen Award to Conduct Novel COVID-19 Decentralized Clinical Study

SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Walgreens Boots Alliance, Inc. (NASDAQ: WBA) securities between October 12, 2023 and June 26, 2024, both dates inclusive (the “Class Period”), have until September 10, 2024 to seek appointment as lead plaintiff of the Walgreens class action lawsuit. Captioned Bhaila v. Walgreens Boots Alliance, Inc., No. 24-cv-05907 (N.D. Ill.), the Walgreens class action lawsuit charges Walgreens as well as certain of Walgreens' top executives with violations of the Securities Exchange Act of 1934.

WBA INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Walgreens Boots Alliance, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

Walgreens Boots Alliance slashed its dividend this year, but it still offers a yield above 9% at recent prices. Medical Properties Trust is a hospital-focused real estate investment trust that yields more than 12% at recent prices.

News for Walgreens Stock (WBA)